ArticleTrials2019

Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients.

Haruko Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.